Gouws Capital LLC Has $4.04 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Gouws Capital LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,676 shares of the company’s stock after selling 730 shares during the quarter. Zoetis makes up 2.7% of Gouws Capital LLC’s investment portfolio, making the stock its 15th largest holding. Gouws Capital LLC’s holdings in Zoetis were worth $4,040,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Vanguard Group Inc. grew its stake in shares of Zoetis by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after buying an additional 414,605 shares in the last quarter. Bank of New York Mellon Corp grew its position in Zoetis by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after acquiring an additional 178,303 shares during the period. Capital Research Global Investors grew its position in Zoetis by 2.3% in the first quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock valued at $685,416,000 after acquiring an additional 90,330 shares during the period. Clearbridge Investments LLC grew its position in Zoetis by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after acquiring an additional 166,517 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Zoetis by 17.3% during the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after purchasing an additional 351,372 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the topic of several research analyst reports. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. raised their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, BTIG Research raised their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $221.44.

Zoetis Price Performance

NYSE ZTS traded down $2.69 during trading on Friday, hitting $171.94. 524,988 shares of the company’s stock were exchanged, compared to its average volume of 2,534,981. The stock’s 50 day moving average price is $187.37 and its two-hundred day moving average price is $179.98. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a market cap of $77.57 billion, a PE ratio of 32.34, a P/E/G ratio of 2.72 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm posted $1.36 earnings per share. The firm’s revenue was up 11.6% compared to the same quarter last year. Research analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is presently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.